Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Adults With Generalized Anxiety Disorder Using Glutamine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with generalized anxiety disorder defined by the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)~* Generalized anxiety disorder is the primary psychiatric disorder.~* Untreated patients or; patients treated with paroxetine, sertraline, citalopram, escitalopram, venlafaxine or duloxetine at least for 6 weeks on a stable dose; or patients treated with any benzodiazepine at least for 4 weeks on a stable dose.~* Hamilton Anxiety Rating Scale score major or equal to 20 and a score major or equal to 2 on items 1 and 2 of the same scale at both screening and baseline.~* Clinical Global Impression-Severity major or equal to 4 at both screening and baseline.~Exclusion Criteria:~* Unable to give informed consent.~* Currently participating in another clinical research.~* Any other psychiatric disorder not included in the Anxiety Disorders section of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Secondary diagnosis of other anxiety disorders are allowed provided the diagnosis is not more prominent than generalized anxiety disorder symptoms.~* Suicide risk as assessed by the researcher at screening or baseline.~* History of substance abuse in the previous six months before the screening visit.~* Suffering a medically relevant or instable disease.~* If woman, being pregnant at screening visit.~* If woman, being breastfeeding.~* A score major or equal to 20 on the Montgomery-Asberg Depression Rating Scale at screening or baseline.~* As judged by a researcher, the patient might not adhere to the intervention or complete follow-up.~* History of use of a banned drug in the past two weeks prior the baseline visit; three weeks in the case of monoamine oxidase inhibitors; one week in the case of fluvoxamine or a tricyclic antidepressant; two weeks for any antipsychotic and; six weeks por long-acting injectable antipsychotics.~* History of use of L-glutamine the most part of the days of the previous month before the baseline visit.~* History of psychotherapy treatment in the past month before the baseline visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Patients in this group will receive flexible doses of L-glutamine ranging from 5 to 25 grams once daily for 8 weeks. L-glutamine is administered as a powder dissolved in water.
- Placebo group (Type: PLACEBO_COMPARATOR): Patients in this group will receive flexible doses of placebo ranging from 5 to 25 grams once daily for 8 weeks. Placebo is administered as a powder dissolved in water.

Based on this trial design, predict the completion outcome and termination type (if applicable).